Market Overview

UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals to Hold; Negative Catalysts Have Passed

Related CBST
Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement
Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc
Making Money With Charles Payne: 12/12/14 (Fox Business)

Cantor Fitzgerald upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Sell to Hold and raised the price target from $37.00 to $38.00.

Cantor Fitzgerald commented, "We believe the company is facing several "investment" years that are likely to adversely impact the bottom line and the stock should therefore only move upwards on evidence of stronger than expected Cubicin growth and major data catalysts (and no significant events are expected until 2H:13). We anticipate an initial downward reaction in the stock after the earnings call, but we are upgrading to a HOLD since we think that the negative catalyst around 2013 guidance visibility has now played out."

Cubist Pharmaceuticals closed at $42.75 on Wednesday.

Latest Ratings for CBST

DateFirmActionFromTo
Dec 2014UBSDowngradesBuyNeutral
Dec 2014OppenheimerDowngradesOutperformMarket Perform
Dec 2014Mizuho SecuritiesDowngradesBuyNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters